GLP-1 Receptor Agonist Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: GLP-1 Receptor Agonist
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-001 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-004 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-003 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-005 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-002 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-004 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eli Lilly And Co | ZEPBOUND | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-003 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |